Start here if you're new
what it is
Lite Strategy used to sell and license cancer drug assets. Now it also holds Litecoin as a reserve asset.
how it gets paid
Last year Lite Strategy made $0 in revenue.
why growth slowed
Revenue fell 100% to $0. Latest quarter: still $0 revenue; loss per share narrowed to -$1.03 vs a deeper prior-year loss—skip clean “% improvement” wording on negative EPS bases.
what just happened
The quarter said $0 revenue and a loss of -$1.03 per share, which is the whole story.
At a glance
C++ balance sheet — some cracks in the foundation
5/100 earnings predictability — expect surprises
ROC reads 86.8% but revenue is $0 — treat as a broken ratio, not proof of returns
-$2.39 fy2025 eps est
$65M fy2024 rev est
xvary composite: 38/100 — weak
What they do
Lite Strategy used to sell and license cancer drug assets. Now it also holds Litecoin as a reserve asset.
The edge here is not scale. It is a tiny cost base. The company has just 4 employees, according to the company profile, so each strategic move can hit a very small expense structure. If you believe management can monetize drug assets or treasury holdings faster than cash burn, that lean setup matters.
How they make money
$0
annual revenue · revenue declined -100.0% last year
The products that matter
holds litecoin reserves
Litecoin Treasury
929,548 LTC
this is the company's disclosed primary asset base. if litecoin moves, the balance-sheet story moves with it.
core asset
legacy drug-development assets
Legacy Oncology Assets
$0 revenue
the legacy pipeline produced $0 revenue on this page. that makes it optionality, not evidence.
optionality
manages treasury strategy
Active Treasury Management
$43M market cap
this is the new investment pitch in practice: a $43M public vehicle trying to convince you the treasury strategy deserves the valuation, not just the listing.
the bet
Key numbers
$0
annual revenue
Revenue → customers paying you → so what: EDGAR says the operating business currently brings in no sales at all.
-$2.39
FY2025 EPS est.
EPS → profit per share → so what: the base-case forecast still has each share losing money over the year.
n/m
operating margin
With $0 revenue, a positive operating margin from a feed is not an operating business margin—use the filing, not this box.
86.8%
return on capital
Return on capital → profit from money invested in the business → so what: this looks elite on paper, but it clashes with zero revenue and needs skepticism.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 4 — safer than 20% of stocks
- price stability 5 / 100
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for LITS right now.
source: institutional data · return history unavailable
What just happened
missed estimates
The quarter said $0 revenue and a loss of -$1.03 per share, which is the whole story.
Latest-quarter revenue was $0. Loss per share was -$1.03 vs a larger loss in the year-ago quarter—describe it as narrowing, not a tidy positive %. Still no operating sales base underneath.
$0
revenue
-$1.03
eps
n/a
n/a
the number that mattered
The key number was $0 revenue because revenue → customer demand in dollars → so what: without sales, every other metric needs an asterisk.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk here is litecoin price exposure inside a company wrapper. this is company-specific because the disclosed primary asset is 929,548 LTC, not a broad operating base.
med
litecoin price drawdowns hit the whole story
you are exposed to 929,548 LTC as the primary asset base. if litecoin falls, balance-sheet confidence falls with it, and there is not much diversification here to absorb the blow.
impact: the stock can reprice on crypto weakness even if nothing else inside the company changes.
med
the pivot can stay a story longer than you expect
the page still shows a former biotech identity, a $65M revenue estimate, and legacy oncology assets at $0 revenue. when the model itself is this unsettled, you are taking execution risk before you even get to valuation risk.
impact: if management cannot turn the pivot into a cleaner operating narrative, the market may stop giving it the benefit of the doubt.
med
thin coverage means weak external anchoring
target data is thin, consensus is sparse, and earnings predictability is 5 / 100. that leaves you with fewer outside reference points and more room for sentiment to swing the stock.
impact: price can move harder and faster because there are fewer stable expectations to act as ballast.
put those together and you get a simple equation: one concentrated asset, one unfinished pivot, and one thin analyst set. that is enough to make a $43M stock move violently.
source: institutional data · regulatory filings · risk analysis
Pay attention to
core metric
929,548 LTC
this is the number that matters first. if the company adds, sells, or reframes this reserve, the whole thesis changes with it.
risk
earnings predictability at 5 / 100
that score tells you reported results may stay messy. if it remains pinned near the floor, your visibility stays poor.
calendar
the next company update
you want clarity on whether management is building an actual treasury framework or just narrating one. last full review on this page: dec 26, 2025.
trend
distance from the $1–$9 range
at $1.53, the stock sits far closer to the low than the high. that tells you sentiment already broke once. watch whether the business gives investors a reason to trust it again.
Analyst rankings
short-term outlook
mixed
analyst target data is thin here. in human-speak: nobody has a firm, widely shared view of fair value.
risk profile
volatile
price stability is 5 / 100 and the 52-week range runs from $1 to $9. this stock does not move like a stable operator.
chart momentum
story-driven
with a $43M market cap and thin coverage, narrative shifts can matter more than traditional trend signals.
earnings predictability
5/100
translation: you should expect unstable quarterly reads until the business model stops changing shape.
source: institutional data
Institutional activity
institutional ownership data for LITS is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$2
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive